Conferences / ASCO 06/09/2026

Experts Review Groundbreaking Data From RASolute 302 and Its Impact on GI Oncology

Key Points

  • The RASolute 302 trial showed daraxonrasib dramatically improved survival compared with standard chemotherapy in patients with pretreated metastatic pancreatic cancer.
  • RASolute 302 and other recent trials in gastrointestinal (GI) cancers showcase the growing role of targeted therapies, and oncologists should screen patients to identify those eligible for novel treatment options.

GI medical oncologists, Charbel Matar, MD, of The George Washington University Hospital, and Deepak Vadehra, DO, of ChristianaCare, met to discuss breaking data from the 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026). While the meeting featured several major updates for GI oncology, the results from the RASolute 302 trial were particularly noteworthy, said Dr. Vadehra. 

The phase 3 RASolute 302 trial evaluated daraxonrasib, an oral RAS(ON) multiselective inhibitor, against standard chemotherapy as second-line therapies in patients with metastatic pancreatic adenocarcinoma. In the trial, daraxonrasib yielded “unprecedented” improvements in overall and progression-free survival compared with chemotherapy for both RAS G12–mutated and wild type patients, according to the ASCO 2026 presentation. 

The dramatic benefit with daraxonrasib in RASolute 302, along with positive findings from other trials like HERIZON-GEA-01 and FIGHT-302, evidence the growing importance of targeted therapy for patients with GI cancers. Moving forward, physicians must incorporate timely comprehensive molecular testing in their practices to identify patients that can benefit from these treatment options, said Dr. Vadehra.